

In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.
Please amend claims 7, 8 and 10-12, and add new claim 13 as follows.

1. (original) A calcium or magnesium salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)-amino]-2-oxoethoxy}phenyl)propanoic acid.
2. (original) A calcium salt of (2S)-2-ethoxy-3-(4-{2-[hexyl(2-phenylethyl)-amino]-2-oxoethoxy}phenyl)propanoic acid.
3. (previously presented) A salt as claimed in either claim 1 or claim 2 which is a solvate, a hydrate, a mixed solvate/hydrate, an anhydrate or an anhydrous form.
4. (previously presented) A salt as claimed in either claim 1 or claim 2 in crystalline or partially crystalline form.
5. (previously presented) A salt as claimed in either claim 1 or claim 2 either in the form of a mixed salt together with a pharmaceutically inactive counterion.
6. (previously presented) A salt as claimed in either claim 1 or claim 2 wherein the pharmaceutically inactive counterion is $[\text{CaCl}]^+$.
7. (currently amended) A pharmaceutical formulation comprising a compound according to either claim 1 or claim 2 in admixture with ~~pharmaceutically acceptable adjuvants, diluents and/or carriers~~ a pharmaceutically acceptable adjuvant, diluent and/or carrier.
8. (currently amended) A method of treating ~~or preventing~~ lipid disorders (dyslipidemia) whether or not associated with insulin resistance comprising the administration of a compound according to either claim 1 or claim 2 to a mammal in need thereof.
9. (canceled).

10. (currently amended) A method of treating or preventing type 2 diabetes comprising administering an effective amount of a compound of ~~formula 1~~ according to either claim 1 or claim 2 to a mammal in need thereof.

11. (currently amended) A pharmaceutical composition comprising a compound according to either claim 1 or claim 2 combined with another therapeutic agent that is useful in the treatment of ~~disorders~~ a disorder associated with the development and progress of atherosclerosis ~~such as hypertension, hyperlipidaemias, dyslipidaemias, diabetes and obesity.~~

12. (currently amended) A pharmaceutical formulation comprising a compound according to claim 5 with ~~pharmaceutically acceptable adjuvants, diluents and/or carriers~~ a pharmaceutically acceptable adjuvant, diluent and/or carrier.

13. (new) A pharmaceutical composition according to claim 11 wherein the disorder associated with the development and progress of atherosclerosis is hypertension, hyperlipidemia, dyslipidemia, diabetes, or obesity.